DK0869942T3 - Som hypolipidemiske midler velegnede 4-[(heterocycloalkyl- eller heteroaromatisk)-substitueret phenyl-]-2-azetidinoner - Google Patents

Som hypolipidemiske midler velegnede 4-[(heterocycloalkyl- eller heteroaromatisk)-substitueret phenyl-]-2-azetidinoner

Info

Publication number
DK0869942T3
DK0869942T3 DK95943048T DK95943048T DK0869942T3 DK 0869942 T3 DK0869942 T3 DK 0869942T3 DK 95943048 T DK95943048 T DK 95943048T DK 95943048 T DK95943048 T DK 95943048T DK 0869942 T3 DK0869942 T3 DK 0869942T3
Authority
DK
Denmark
Prior art keywords
heterocycloalkyl
azetidinone
alkylene
substituted
heteroaromatic
Prior art date
Application number
DK95943048T
Other languages
English (en)
Inventor
Wayne D Vaccaro
Duane A Burnett
John W Clader
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0869942T3 publication Critical patent/DK0869942T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
DK95943048T 1994-12-21 1995-12-18 Som hypolipidemiske midler velegnede 4-[(heterocycloalkyl- eller heteroaromatisk)-substitueret phenyl-]-2-azetidinoner DK0869942T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/361,265 US5656624A (en) 1994-12-21 1994-12-21 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
PCT/US1995/016007 WO1996019450A1 (en) 1994-12-21 1995-12-18 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Publications (1)

Publication Number Publication Date
DK0869942T3 true DK0869942T3 (da) 2002-03-25

Family

ID=23421327

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95943048T DK0869942T3 (da) 1994-12-21 1995-12-18 Som hypolipidemiske midler velegnede 4-[(heterocycloalkyl- eller heteroaromatisk)-substitueret phenyl-]-2-azetidinoner

Country Status (10)

Country Link
US (1) US5656624A (da)
EP (1) EP0869942B1 (da)
JP (2) JP3992732B2 (da)
AT (1) ATE213230T1 (da)
AU (1) AU4419896A (da)
DE (1) DE69525479T2 (da)
DK (1) DK0869942T3 (da)
ES (1) ES2168396T3 (da)
PT (1) PT869942E (da)
WO (1) WO1996019450A1 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
FR2762336B1 (fr) * 1997-04-21 1999-06-11 Francois Trantoul Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
RS50864B (sr) * 2000-12-21 2010-08-31 Sanofi-Aventis Deutschland Gmbh. Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CN100522159C (zh) * 2001-01-26 2009-08-05 先灵公司 取代的氮杂环丁烷酮化合物在制备治疗谷甾醇血症的药物中的应用
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
KR100590342B1 (ko) 2001-03-28 2006-06-15 쉐링 코포레이션 아제티딘온 중간체 화합물의 에난티오-선택적 합성법
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7176194B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US7671047B2 (en) * 2002-06-19 2010-03-02 Sanofi-Aventis Deutschland Gmbh Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
US7176193B2 (en) * 2002-06-19 2007-02-13 Sanofi-Aventis Deutschland Gmbh Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1680189A2 (en) * 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EA010026B1 (ru) * 2003-11-10 2008-06-30 Майкробиа, Инк. 4-биарилил-1-фенилазетидин-2-оны
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
CA2550215A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
CN102558075A (zh) 2004-12-03 2012-07-11 先灵公司 作为cb1拮抗剂的取代哌嗪
TW200726746A (en) * 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1962835A2 (en) * 2005-12-21 2008-09-03 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3 receptor antagonist/inverse agonist
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
WO2007100807A2 (en) * 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
KR20080096851A (ko) * 2006-03-06 2008-11-03 테바 파마슈티컬 인더스트리즈 리미티드 에제티미베 조성물
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AR062790A1 (es) * 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
JP2010503679A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛および脂質代謝障害を処置する際に有用なアゼチジン誘導体およびアゼチドン誘導体
MX2009002921A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
EP2066668A1 (en) * 2006-09-15 2009-06-10 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
DE102007063671A1 (de) * 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
SI2844233T1 (sl) 2012-05-01 2020-08-31 Althera Life Sciences, Llc Peroralna tableta, sestavljena iz fiksne kombinacije rosuvastatina in ezetimiba za zdravljenje hiperlipidemije in bolezni srca in ožilja
CN105878235B (zh) * 2016-04-19 2019-01-15 清远职业技术学院 对n咪唑苯甲醛缩邻甲苯胺希夫碱在抗沙门氏菌方面的应用
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
CN105878236B (zh) * 2016-04-19 2018-10-26 清远职业技术学院 对n咪唑苯甲醛缩邻甲苯胺希夫碱在抗金黄色葡萄球菌方面的应用
CA3133000A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
TW223059B (da) * 1991-07-23 1994-05-01 Schering Corp
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents

Also Published As

Publication number Publication date
AU4419896A (en) 1996-07-10
DE69525479D1 (de) 2002-03-21
PT869942E (pt) 2002-07-31
WO1996019450A1 (en) 1996-06-27
JP4619371B2 (ja) 2011-01-26
ATE213230T1 (de) 2002-02-15
DE69525479T2 (de) 2002-10-02
EP0869942B1 (en) 2002-02-13
JPH10511938A (ja) 1998-11-17
EP0869942A1 (en) 1998-10-14
ES2168396T3 (es) 2002-06-16
JP2007091757A (ja) 2007-04-12
MX9704482A (es) 1997-10-31
JP3992732B2 (ja) 2007-10-17
US5656624A (en) 1997-08-12

Similar Documents

Publication Publication Date Title
DK0869942T3 (da) Som hypolipidemiske midler velegnede 4-[(heterocycloalkyl- eller heteroaromatisk)-substitueret phenyl-]-2-azetidinoner
DE69830504D1 (de) Antithrombotische mitteln
ATE306261T1 (de) Antithrombosemittel
SE9801474D0 (sv) Quinoline Derivatives
CA2200707A1 (en) Novel prostaglandin synthase inhibitors
DE59402222D1 (de) Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AU1973997A (en) Pentafluorobenzenesulfonamides and analogs
DK0641328T3 (da) Broforbundne, azabicykliske derivater som substans P-antagonister
ES2132415T3 (es) Nuevos derivados de 5-pirrolil-2-piridilmetilsulfinilbencimidazol.
GEP20094676B (en) Piperidine compounds and pharmaceutical compositions containing them
DK0874812T3 (da) Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
TR200402758T4 (tr) Hipokolesterolemik ajanlar olarak faydalı şekerle ikame edilen 2-azetidinonlar.
WO2005066166A3 (en) 3-quinuclidinyl amino-substituted biaryl derivatives
DE59304311D1 (de) N-substituierte 3-azabicyclo[3.2.0]heptan-derivate als neuroleptika
ATE250610T1 (de) Kaliumkanal-blockierende mittel
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
FI970449A0 (fi) N-substituoituja atsabisykloheptaanijohdannaisia, jotka ovat käyttökelpoisia neuroleptisinä aineina
DK0937057T3 (da) Hidtil ukendte (-)-enantiomerer af cis-3,4-chromanderivater anvendelige i forebyggelse eller behandling af østrogenrelaterede sygdomme eller syndromer
EA200400409A1 (ru) Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ATE234320T1 (de) Beta,beta-disubstituierte derivate von 9-deoxo-9a-n-ethenyl-9a-aza-9a-homoerythromycin a
CA2207627A1 (en) 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
TR199701185A2 (xx) Sefalosporin piridinyum t�revleri.